ID: ALA143730

Max Phase: Preclinical

Molecular Formula: C10H4N4O2

Molecular Weight: 212.17

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1c2nccnc2C(=O)c2nccnc21

Standard InChI:  InChI=1S/C10H4N4O2/c15-9-5-6(12-2-1-11-5)10(16)8-7(9)13-3-4-14-8/h1-4H

Standard InChI Key:  MCDLMKSICPMXGF-UHFFFAOYSA-N

Associated Targets(Human)

PC-14 387 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MKN-45 2102 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 212.17Molecular Weight (Monoisotopic): 212.0334AlogP: 0.04#Rotatable Bonds: 0
Polar Surface Area: 85.70Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: -0.41CX LogD: -0.41
Aromatic Rings: 2Heavy Atoms: 16QED Weighted: 0.52Np Likeness Score: 0.02

References

1. Yoo HW, Suh ME, Park SW..  (1998)  Synthesis and cytotoxicity of 2-methyl-4, 9-dihydro-1-substituted-1H-imidazo[4,5-g]quinoxaline-4,9-diones and 2,3-disubstituted-5,10-pyrazino[2,3-g]quinoxalinediones.,  41  (24): [PMID:9822542] [10.1021/jm970695n]

Source